Product Description
BEBT‑730 — URAT1 | Hyperuricemia & Gout: In 293T‑hURAT1 cells, 10 nM achieved 93% URAT1 mRNA reduction. In a mouse hyperuricemia model, a single 5 mg/kg dose normalized serum urate, comparable to daily benzbromarone. A 4-week mouse tox study (200 mg/kg ×3) showed no clinical or clinical‑chemistry liabilities; next steps include NHP PK/PD, GLP tox, and CMC for IND. (Sourced from: http://www.bebettermed.com/#pipeline)
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: BeBetter Med
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Gout
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|